As a company committed to improving people’s lives, Takeda will continue to support the recovery of the areas affected by the Great East Japan Earthquake.
Press Releases
- January 27, 2012
Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan - January 24, 2012
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications - January 18, 2012
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth - January 18, 2012
New Drug Application Approval for AZILVA® in Japan, a Treatment of Hypertension - January 10, 2012
European Commission Adopts European Medicines Agency’s Opinion Confirming Pioglitazone-Containing Medicines Remain a Valid Treatment Option for Appropriate Type 2 Diabetes Patients
Information
- February 1, 2012
3rd Quarter of FY2011 financial results announcement at 3:00pm & conference call from 4:30pm
Worldwide
Locations Worldwide
Stock
Performance
- 01/27 15:00 (TSE 1st)
- Value : 3,315 JPY
- Net change : +5 JPY
- JIJI PRESS,LTD
Relationship with Society
Introducing Takeda's corporate citizenship and social responsibility
